2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

sponse to exemestane vs tamoxifen. Presented at: 2008 San Antonio Breast
Cancer Symposium.
26. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive
value of centrally reviewed Ki-67 labelling index in postmenopausal women
with endocrine-responsive breast cancer: Results form Breast International
Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol.
2008;26:5569-5575.
27. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant
recurrence using the 21-gene recurrence score in node-negative and nodepositive
postmenopausal patients with breast cancer treated with anastrozole
or tamoxifen: A TransATAC study. J Clin Oncol. 2010;28:1829-1834.
28. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile
of anastrozole and tamoxifen as adjuvant treatment for early-stage breast
cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:
633-643.
29. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of
Clinical Oncology 2003 update on the role of bisphosphonates and bone health
issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
30. Goss PE, Ingle JN, Chapman J-AW, et al. Final analysis of NCIC
MA.27; a randomised phase III trial of exemestane versus anastrozole in
postmenopausal women with hormone receptor positive primary breast
cancer. Presented at San Antonio Breast Cancer Symposium 2010, Abstract
S1-1.
31. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in
postmenopausal women after five years of tamoxifen therapy for early-stage
breast cancer. N Engl J Med. 2003;349:1793-1802.
32. Goss PE, Ingle JN, Martino S, et al. Randomised trial of letrozole
following tamoxifen as extended adjuvant therapy in receptor-positive breast
cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst.
2005;97:1262-1271.
33. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended
adjuavnt therapy according to estrogen receptor and progesterone receptor
status of the primary tumour: National Cancer Institute of Canada Trials
Group MA. 17. J Clin Oncol. 2006;25:2006-2011.
26
STEPHEN R. JOHNSTON
34. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment
with letrozole improved outcome in women with early stage breast cancer who
completes 5 years of tamoxifen. J Clin Oncol. 2008;26:1948-1955.
35. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with
anastrozole among postmenopausal breast cancer patients; results from the
randomised Austrian Breast and Colorectal Cancer Study Group Trial 6a.
J Natl Cancer Inst. 2007;99:1845-1853.
36. Mamounas EP, Jeong J-H, Wickerham L, et al. Benefit from exemestane
as extended adjuvant therapy after 5 years of adjuvant tamoxifen;
intention-to-treat analysis of the National Surgical Adjuvant Breast and
Bowel Project B-33 Trial. J Clin Oncol. 2008;26:1965-1971.
37. Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy
for pre-menopausal women with axillary lymph-node positive, steroid hormone
receptor positive breast cancer: Results from INT 0101 (E5188). J Clin
Oncol. 2005;23:2973-2982
38. International Breast Cancer Study Group. Adjuvant chemotherapy
followed by goserelin versus either modality alone for pre-menopausal lymph
node negative breast cancer—a randomised trial. J Natl Cancer Inst. 2003;
95:1833-1846.
39. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormonereleasing
hormone agonists as adjuvant treatment in premenopausal patients
with hormone-receptor-positive breast cancer: A meta-analysis of individual
patient data from randomised adjuvant trials. Lancet. 2007;369:1711-1723.
40. Sotiriou C and Pusztai L. Gene expression signatures in breast cancer.
N Engl J Med. 2009;360:790-800.
41. Goldhirsch A, Wood WC, Coates RD, et al. Strategies for subtypes -
dealing with the diversity of breast cancer; highlights of the St Galen
International Expert Consensus on the Primary Therapy of Early Breast
Cancer 2011. Ann Oncol. 2011;22:1736-1747.
42. Albain K, Barlow WE, Shak S, et al. Prognostic and predictive value of
the 21-gene recurrence score assay in postmenopausal women with nodepositive,
oestrogen-receptor positive breast cancer on chemotherapy; a retrospective
analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.